Full-Time

Manager of Virus Clearance Services

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Glasgow, UK

Hybrid

Some hybrid working is available.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Inventory Management
Word/Pages/Docs
Excel/Numbers/Sheets

Get referred to Sartorius

See people who can refer or advise you

Requirements
  • A Master's degree in biology, biopharmaceutical, biotechnology, or a relevant discipline.
  • At least 8 years of work experience in the biotechnology or pharmaceutical industry, combined with experience managing and leading a team in a GxP environment.
  • Experience in process development with biological products, especially downstream processing.
  • Experience maintaining quality management systems.
  • Strong leadership skills and the ability to build relationships with internal and external stakeholders.
  • Strong project management and organisational skills.
  • Ability to comprehend and draw conclusions from scientific and numerical data.
  • Strong written and verbal communication skills.
  • Excellent skills in Microsoft packages such as Word and Excel.
  • The successful candidate must have the right to work in the United Kingdom.
Responsibilities
  • Lead and manage GLP-compliant operations for Confidence Virus Clearance UK, ensuring appropriate staffing, facilities, equipment, and materials are in place to deliver regulatory studies effectively and on time.
  • Provide line management and leadership to approximately six direct reports, ensuring team capability, training, development, and accurate records of qualifications and experience are maintained.
  • Oversee the planning and execution of GLP studies, including resource allocation, coordination with Study Directors and Principal Investigators, and ensuring study plans, amendments, and master schedules are properly approved and maintained.
  • Ensure full regulatory compliance with GLP standards and relevant guidelines, including ICH Q5A, GLP SI 3106, and OECD requirements.
  • Own and maintain quality systems and assurance programmes, including SOP approval, deviations, change controls, audits, and ensuring Quality Assurance activities are performed in line with GLP principles.
  • Act as the site lead for inspections and audits, hosting regulatory and customer inspections and acting as a named individual on the operator licence where required.
  • Ensure operational and commercial oversight of the facility, including supplier and test site approval, inventory and consumables management, cost control initiatives, and general site financial awareness.
  • Represent the function internally and externally, collaborating with internal stakeholders and supporting customer interactions as a technical expert in meetings and industry events.
  • Coordinate with sister Virus Clearance sites globally to harmonise procedures and share knowledge relating to viral clearance and viral safety.
Desired Qualifications
  • A PhD in biology, biopharmaceutical, biotechnology, or a relevant discipline.
  • Experience hosting audits, including MHRA and FDA audits.
  • Experience with commercial aspects of facility management.

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2026 sales reached €1.8109 billion, with profitable growth and rising free cash flow.
  • January 2026 ISCC Plus certification expanded bio-circular filters and single-use products across Europe.
  • June 2025 Aubagne expansion and July 2026 launches expand capacity for biologics customers.

What critics are saying

  • Bio-Rad still owned roughly 38% of ordinary shares on June 30, 2026.
  • July 2026 Bio-Rad restructuring signals persistent pressure to monetize its Sartorius stake.
  • 2025 demand remained below pre-pandemic levels, forcing hiring freezes' reversal into selective production additions.

What makes Sartorius unique

  • Bioprocess Solutions drove 80% of 2026 sales, anchored by single-use workflows.
  • March 2026 CHO host line triples productivity, strengthening cell-line development economics.
  • June 2026 LFB collaboration links CLD, analytics, and GMP manufacturing into one pathway.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Jul 23rd, 2026
Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS
May 15th, 2026
Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG
May 6th, 2026
Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.